Stock Analysis on Net

Cytokinetics Inc. (NASDAQ:CYTK)

$22.49

This company has been moved to the archive! The financial data has not been updated since November 3, 2023.

Enterprise Value to FCFF (EV/FCFF)

Microsoft Excel

Paying user area


We accept:

Visa Mastercard American Express Maestro Discover JCB PayPal Google Pay
Visa Secure Mastercard Identity Check American Express SafeKey

Free Cash Flow to The Firm (FCFF)

Cytokinetics Inc., FCFF calculation

US$ in thousands

Microsoft Excel
12 months ended: Dec 31, 2022 Dec 31, 2021 Dec 31, 2020 Dec 31, 2019 Dec 31, 2018
Net loss
Net noncash charges
Changes in operating assets and liabilities
Net cash provided by (used in) operating activities
Cash paid for interest, net of tax1
Purchases of property and equipment
Sales of property and equipment
Right-of-use assets recognized in exchange for finance lease obligations
Free cash flow to the firm (FCFF)

Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).


The financial data demonstrates clear volatility in cash flow performance over the five-year period under review. There is a notable fluctuation in operating cash flows and free cash flow to the firm, indicating changing operational efficiency and investment dynamics.

Net Cash Provided by (Used in) Operating Activities

This item exhibits significant negative cash flow in the years 2018, 2019, 2021, and 2022, with an anomalous positive cash flow in 2020. The negative values in 2018 and 2019 were approximately -101 million and -91 million USD respectively, suggesting outflows from core operational activities during that period.

In 2020, the trend shifted, indicating a positive cash inflow of roughly 9 million USD from operating activities. However, this positive movement did not persist, as the figures reverted to significant negative values in 2021 and 2022, reaching approximately -142 million USD and worsening to -299 million USD respectively. This reversal signals potential operational challenges or increased expenditure levels in recent years.

Free Cash Flow to the Firm (FCFF)

The FCFF closely mirrors the trend observed in operating cash flows. Negative free cash flow was recorded in 2018 and 2019 at around -99 million and -89 million USD respectively, denoting substantial cash outflow after accounting for capital expenditures.

During 2020, the firm experienced a positive FCFF of approximately 7.5 million USD, which aligns with the positive net operating cash flow in that year. Nonetheless, this improvement was temporary, as the FCFF deteriorated again in 2021 and 2022 to approximately -184 million and -297 million USD respectively, reflecting increased cash consumption and potential expansion or increased capital spending.

The overall analysis indicates that the organization faced significant operating cash challenges for most years, with only a brief recovery in 2020. The escalating negative cash flows in 2021 and 2022 signal increased financial strain, potentially from intensified investment activities or operational expenses. This pattern warrants a careful review of cash management strategies and cost control measures to enhance liquidity stability going forward.


Interest Paid, Net of Tax

Cytokinetics Inc., interest paid, net of tax calculation

US$ in thousands

Microsoft Excel
12 months ended: Dec 31, 2022 Dec 31, 2021 Dec 31, 2020 Dec 31, 2019 Dec 31, 2018
Effective Income Tax Rate (EITR)
EITR1
Interest Paid, Net of Tax
Cash paid for interest, before tax
Less: Cash paid for interest, tax2
Cash paid for interest, net of tax

Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).

1 See details »

2 2022 Calculation
Cash paid for interest, tax = Cash paid for interest × EITR
= × =


The data indicates a clear upward trend in the amount of cash paid for interest, net of tax, over the five-year period examined. Starting from a value of 2,877 thousand US dollars in 2018, this outflow significantly increased to 15,165 thousand US dollars by the end of 2022. This represents more than a fivefold increase over the period, suggesting rising borrowing costs, increased debt levels, or changes in interest rates impacting the company.

The year-to-year increases are notable, with a moderate rise from 2018 to 2019, followed by a more substantial increase in 2020. The amounts paid in 2021 showed a slight decline relative to 2020 but remained considerably higher than in the earlier years. The most significant annual increase occurred between 2021 and 2022, indicating an acceleration in interest-related cash outflows during the most recent period.

Regarding the effective income tax rate (EITR), no data was provided, which limits the ability to analyze tax-related trends or their effect on the company’s financial performance. Without this information, any insights related to tax strategy, tax burden, or changes in tax rates remain unavailable.


Enterprise Value to FCFF Ratio, Current

Cytokinetics Inc., current EV/FCFF calculation, comparison to benchmarks

Microsoft Excel
Selected Financial Data (US$ in thousands)
Enterprise value (EV)
Free cash flow to the firm (FCFF)
Valuation Ratio
EV/FCFF
Benchmarks
EV/FCFF, Competitors1
AbbVie Inc.
Amgen Inc.
Bristol-Myers Squibb Co.
Danaher Corp.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals Inc.
EV/FCFF, Sector
Pharmaceuticals, Biotechnology & Life Sciences
EV/FCFF, Industry
Health Care

Based on: 10-K (reporting date: 2022-12-31).

1 Click competitor name to see calculations.

If the company EV/FCFF is lower then the EV/FCFF of benchmark then company is relatively undervalued.
Otherwise, if the company EV/FCFF is higher then the EV/FCFF of benchmark then company is relatively overvalued.


Enterprise Value to FCFF Ratio, Historical

Cytokinetics Inc., historical EV/FCFF calculation, comparison to benchmarks

Microsoft Excel
Dec 31, 2022 Dec 31, 2021 Dec 31, 2020 Dec 31, 2019 Dec 31, 2018
Selected Financial Data (US$ in thousands)
Enterprise value (EV)1
Free cash flow to the firm (FCFF)2
Valuation Ratio
EV/FCFF3
Benchmarks
EV/FCFF, Competitors4
AbbVie Inc.
Amgen Inc.
Bristol-Myers Squibb Co.
Danaher Corp.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals Inc.
EV/FCFF, Sector
Pharmaceuticals, Biotechnology & Life Sciences
EV/FCFF, Industry
Health Care

Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).

1 See details »

2 See details »

3 2022 Calculation
EV/FCFF = EV ÷ FCFF
= ÷ =

4 Click competitor name to see calculations.


Enterprise Value (EV)
The enterprise value exhibited a strong upward trend over the analyzed period. Starting at approximately 174 million US dollars at the end of 2018, it increased significantly each year, reaching nearly 787.6 million by the end of 2019, and further expanding to over 1 billion by the end of 2020. The growth accelerated from 2020 to 2021, with the enterprise value more than doubling to around 2.64 billion. By the end of 2022, the enterprise value had climbed to approximately 3.93 billion US dollars, indicating a substantial increase in the company’s market valuation or total capital invested over the five-year span.
Free Cash Flow to the Firm (FCFF)
The free cash flow to the firm showed considerable volatility and generally negative values over the years, highlighting ongoing cash outflows. In 2018 and 2019, the company faced substantial negative FCFF of about -99.2 million and -89.5 million US dollars, respectively. A notable positive cash flow emerged in 2020, with FCFF turning positive to approximately 7.5 million US dollars, reflecting a temporary improvement in operational cash generation or investment flows. However, this positive cash flow was short-lived, as FCFF again declined sharply to negative 183.5 million in 2021 and further worsened to nearly -296.7 million in 2022. This suggests increased cash expenditures or investments that were not offset by operating cash inflows during these years.
EV to FCFF Ratio
The ratio of enterprise value to free cash flow to the firm (EV/FCFF) was only calculable in 2021, where it reached an exceptionally high level of approximately 133.6. This unusually high multiple may reflect the combination of a very high enterprise value relative to substantially negative or low positive free cash flow, implying that investors or market participants assigned a large valuation despite limited or negative cash generation. Data is not available to assess this ratio in the other years, precluding a more complete trend analysis.
Summary of Financial Trends
Overall, the data reveals a rapidly increasing enterprise value, suggesting strong growth expectations or significant changes in capital structure or market perception. Conversely, the firm’s free cash flow profile was predominantly negative, except for one year, indicating challenges in generating consistent positive cash flow from operations after accounting for investments. The combination of rising valuation and weak cash flow performance might indicate early-stage investment phases, heavy spending on development, or other factors that suppress free cash flow in the near term while market value appreciates. The available EV/FCFF multiple in 2021 highlights a potential disconnect between valuation and cash flow, possibly suggesting heightened risk or speculative premium in the company’s market valuation during that period.